Proceedings of the National Academy of Sciences · 2013 · 104 citations · 40 references
MedicineCancer BiologyOncologyChemotherapyMolecular OncologyNeuro-oncologyGlioblastomaHypoxia AdaptationMalignant NeoplasmsMicrorna BiologyMicrorna-mediated RegulationSignal Transduction In CancerGlioblastoma HypoxiaHypoxia-inducible Factor ActivationHypoxia-inducible Factor RegulationHypoxia-inducible Factor SignalingHypoxia-mediated ResistanceMicrorna In CancerTemozolomide TherapyTumor Microenvironment Hypoxia
Glioblastoma multiforme (GBM) and the mesenchymal GBM subtype in particular are highly malignant tumors that frequently exhibit regions of severe hypoxia and necrosis. Because these features correlate with poor prognosis, we investigated microRNAs whose expression might regulate hypoxic GBM cell survival and growth. We determined that the expression of microRNA-218 (miR-218) is decreased significantly in highly necrotic mesenchymal GBM, and orthotopic tumor studies revealed that reduced miR-218 levels confer GBM resistance to chemotherapy. Importantly, miR-218 targets multiple components of receptor tyrosine kinase (RTK) signaling pathways, and miR-218 repression increases the abundance and activity of multiple RTK effectors. This elevated RTK signaling also promotes the activation of hypoxia-inducible factor (HIF), most notably HIF2α. We further show that RTK-mediated HIF2α regulation is JNK dependent, via jun proto-oncogene. Collectively, our results identify an miR-218-RTK-HIF2α signaling axis that promotes GBM cell survival and tumor angiogenesis, particularly in necrotic mesenchymal tumors.
40
Roel G.W. Verhaak, Katherine A. Hoadley, Elizabeth Purdom et al. · Cancer Cell · 2010 · 7.7K citations · Full text
<i>MGMT</i> Gene Silencing and Benefit from Temozolomide in Glioblastoma
Monika E. Hegi, Annie‐Claire Diserens, Thierry Gorlia et al. · New England Journal of Medicine · 2005 · 7.3K citations · Full text
Hua Zhong, Kelly A. Chiles, David M. Feldser et al. · PubMed · 2000 · 1.5K citations